Utilization of self-sampling kits for HPV testing in cervical cancer screening – pilot study


Authors: H. Ondryášová;  V. Koudelakova;  J. Drábek;  P. Vaněk;  R. Slavkovský;  M. Hajdůch
Authors‘ workplace: Ústav molekulární a translační medicíny, LF UP a FN, Klastr MedChemBio, Olomouc-Holice, vedoucí doc. MUDr. Marián Hajdúch, Ph. D.
Published in: Ceska Gynekol 2015; 80(6): 436-443

Overview

Objective:
To get initial experience with alternative sampling (self-sampling) for HPV testing as the means of cervical cancer screening program.

Design:
Original work.

Setting:
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc.

Methods:
Based on expression of interest, 215 self-sampling kits were posted to women. Evalyn® Brush Vaginal swabs obtained by self-sampling were analyzed for the presence of HPV infection by Cobas 4800 HPV (Roche) followed by genotyping using PapilloCheck® HPV-Screening (Greiner Bio-One). Sixty women randomly chosen from our sample were sent a questionnaire focused on their experience with self-sampling.

Results:
One hundred seventy-four of 215 (81%) distributed self-sampling devices have been delivered to analysis. All cervicovaginal swabs were sampled correctly and it was possible to analyze them by Cobas 4800 HPV test. Similarly, 98% (171/174) samples were analyzable by PapilloCheck® HPV-Screening.

One hundred twenty-five (72%) of 174 tested samples were HPV negative. Low risk HPV infection was detected only in 7 samples (4%), and high risk HPV (hrHPV) infection was present in 42 samples (24%). The most frequently detected hrHPV genotypes were HPV16 (11/42; 26%) and HPV53 (6/42; 14%). HrHPV co-infection was detected in 10 cases, in 5 of them lrHPV infection was find also.

Of the 60 questionnaires, 48 (80%) were returned. From this group, 47 (98%) women rated their experience with self-sampling device as good to excellent. User manual of self-sampling device was considered good to excellent by all women (100%). All women also rated the convenience of self-sampling device using as good to excellent. As expected, most of the women (n = 42 [88%]) preferred self-sampling to physician sampling.

Conclusion:
Cervicovaginal self-sampling leads to valid results of HPV screening using two molecular genetics methods and was accepted by Czech women very well. The self-sampling as an opportunity to participate in cervical cancer screening could increase the attendance of the screening program and would help to reduce the incidence and mortality for this disease in the Czech population.

Keywords:
cervical cancer, cervical cancer screening, self-sampling, human papillomavirus, HPV, cytology, PCR


Sources

1. Anttila, A., Pukkala, E., Söderman, B., et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J Cancer, 1999, 83, p. 59–65.

2. Arbyn, M., Ronco, G., Anttila, A., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 2012, 30 Suppl 5, p. F88–F99.

3. Arbyn, M., de Sanjosé, S., Saraiya, M., et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer, 2012, 131, p. 1969–1982.

4. Arbyn, M., Raifu, AO., Weiderpass, E., et al. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer, 2009, 45, p. 2640–2648.

5. Bruni, L., Barrionuevo-Rosas, L., Albero, G., et al. Human papillomavirus and related diseases in the world. Summary report 2015-04-08. Information Centre on HPV and Cancer (HPV Information Centre) 2015.

6. Bulk, S., Visser, O., Rozendaal, L., et al. Cervical cancer in the Netherlands 1989–1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer, 2005, 113, p. 1005–1009.

7. Castellsagué, X., Díaz, M., de Sanjosé, S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J National Cancer Institute, 2006, 98, p. 303–315.

8. Cogliano, V., Baan, R., Straif, K., et al. Carcinogenicity of human papillomaviruses. Lancet Oncol, 2005, 6, p. 204.

9. Cuzick, J., Clavel, C., Petry, K., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer, 2006, 119, p. 1095–1101.

10. Dalstein, V., Merlin, S., Bali, C., et al. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods, 2009, 156, p. 77–83.

11. Duskova, J., Bekova, A., Dvorak, V., et al. Results of the Czech National Cervical Cancer screening programme. Klin Onkol, 2014, 27, Suppl. 2, p. 79–86.

12. Geraets, DT., Cuschieri, K., de Koning, MN., et al. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol, 2014, 52, p. 3996–4002.

13. Gok, M., Heideman, DA., van Kemenade, FJ., et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ, 2010, 340, p. c1040.

14. Gok, M., van Kemenade, FJ., Heideman, DA., et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer, 2012, 130, p. 1128–1135.

15. http: and globocan.iarc.fr/. 18-5-0015. (GENERIC). Ref Type: Report.

16. Majek, O., Dvorak, V., Dusek, L., et al. Cervarix.cz – Program cervikálního screeningu v České republice. Int J Lab Hematol, 6-5-2015. (GENERIC). Ref Type: Online Source.

17. Munoz, N., Bosch, FX., Castellsagué, X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer, 2004, 111, p. 278–285.

18. Petignat, P., Faltin, DL., Bruchim, I., et al. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol, 2007, 105, p. 530–535.

19. Peto, J., Gilham, C., Fletcher, O., Matthews, FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet, 2004, 364, p. 249–256.

20. Preisler, S., Rebolj, M., Untermann, A., et al. Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. PloS One, 2013, 8, p. e59765.

21. Rijkaart, DC., Berkhof, J., van Kemenade, FJ., et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer, 2012, 130, p. 602–610.

22. Rijkaart, DC., Berkhof, J., Rozendaal, L., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol, 2012, 13, p. 78–88.

23. Ronco, G., Giorgi-Rossi, P., Carozzi, F., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol, 2010, 11, p. 249–257.

24. Rossi, PG., Marsili, LM., Camilloni, L., et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Brit J Cancer, 2011, 104, p. 248–254.

25. Snijders, PJ., Verhoef, VM., Arbyn, M., et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer, 2013, 132, p. 2223–2236.

26. Tachezy, R., Smahelova, J., Kaspirkova, J., Salakova, M. Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women. PloS One, 2013, 8, p. e79156.

27. van Baars, R., Bosgraaf, RP., ter Harmsel, BW., et al. Dry storage and transport of a cervicovaginal self-sample by use of the evalyn brush, providing reliable human papillomavirus detection combined with comfort for women. J Clin Microbiol, 2012, 50, p. 3937–3943.

28. Walboomers, JM., Jacobs, MV., Manos, MM., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189, p. 12–19.

Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account